Azilsartan

Share on Facebook Share on Twitter Email
Top
Azilsartan medoxomil
Systematic (IUPAC) name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate
Clinical data
Trade names Edarbi
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611028
Licence data US FDA:link
Pregnancy cat. C (1st trimester)
D (2nd/3rd trimester) (US)
Legal status -only (US)
Routes Oral
Identifiers
CAS number 863031-21-4 YesY
ATC code C09CA09
PubChem CID 11238823
ChemSpider 9413866 YesY
UNII F9NUX55P23 YesY
Chemical data
Formula C30H24N4O8 
Mol. mass 568.53 g/mol
SMILES eMolecules & PubChem
 YesY (what is this?)  (verify)

Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension that was developed by Takeda.

It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]

Mechanism of action

Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Free azilsartan, the active moiety

References



Post a question - any question - to the WikiAnswers community:

Copyrights: